Teladoc Health, Inc. (TDOC) Return on Equity (ROE): -12.81%
Is Teladoc Health, Inc.’s return on equity (ROE) high or low?
Teladoc Health, Inc.'s return on equity (ROE) of -12.81% is 89% above its 5-year average of -114.78%, near the high end of its 5-year range (-591.90%–-2.67%).
As of Tuesday, June 23, 2026. 68.61% above its 12-month average of -40.81%.
TDOC Return on Equity (ROE) Chart
TDOC Average Return on Equity (ROE) Chart
TDOC Current vs Average Return on Equity (ROE) Chart
TDOC Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-12.81%
RETURN ON EQUITY (ROE) AVG TTM
-40.81%
RETURN ON EQUITY (ROE) AVG 3Y
-170.75%
RETURN ON EQUITY (ROE) AVG 5Y
-114.78%
RETURN ON EQUITY (ROE) AVG 10Y
-71.98%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+68.61%
CURRENT VS 3Y AVG
+92.50%
CURRENT VS 5Y AVG
+88.84%
CURRENT VS 10Y AVG
+82.20%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TDOC Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Teladoc Health, Inc. (TDOC) | $1.37B | -12.81% | -40.81% | -170.75% | -114.78% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.03B | -47.65% | -45.75% | -30.11% | -18.95% |
| Shoulder Innovations, Inc. (SI)vs › | $366.44M | -33.14% | -52.50% | -47.15% | -47.15% |
| TransMedics Group, Inc. (TMDX)vs › | $2.61B | 34.80% | 27.86% | 4.54% | -12.45% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -721.75% | 348.35% | 157.32% | 61.09% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.48B | -2.97% | 25.09% | 5.57% | 0.40% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.60B | 2.46% | -8.94% | -15.72% | 1.14% |
| Oscar Health, Inc. (OSCR)vs › | $7.63B | -2.37% | -21.41% | -36.14% | -25.75% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | -72.74% | -651.33% | -315.37% | -198.08% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.75B | -6.28% | -2.13% | 6.32% | 9.65% |
Return Analysis
ROE
-12.8%
ROA
-6.1%
Teladoc Health, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Teladoc Health, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Teladoc Health, Inc. (TDOC)?
- The return on equity (ROE) for TDOC stock is -12.81%.
- Is Teladoc Health, Inc.'s return on equity (ROE) high or low?
- Teladoc Health, Inc.'s return on equity (ROE) of -12.81% is 89% above its 5-year average of -114.78%, near the high end of its 5-year range (-591.90%–-2.67%).
- What is the TTM average return on equity (ROE) for Teladoc Health, Inc. (TDOC)?
- The TTM average return on equity (ROE) for TDOC stock is -40.81%.
- What is the 3Y average return on equity (ROE) for Teladoc Health, Inc. (TDOC)?
- The 3Y average return on equity (ROE) for TDOC stock is -170.75%.
- What is the 5Y average return on equity (ROE) for Teladoc Health, Inc. (TDOC)?
- The 5Y average return on equity (ROE) for TDOC stock is -114.78%.
- What is the 10Y average return on equity (ROE) for Teladoc Health, Inc. (TDOC)?
- The 10Y average return on equity (ROE) for TDOC stock is -71.98%.
Teladoc Health, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -14.46% |
| 2024-12-31 | -67.15% |
| 2023-12-31 | -9.47% |
| 2022-12-31 | -591.90% |
| 2021-12-31 | -2.67% |
| 2020-12-31 | -3.05% |
| 2019-12-31 | -9.75% |
| 2018-12-31 | -9.58% |
| 2017-12-31 | -19.11% |
| 2016-12-31 | -32.15% |
| 2015-12-31 | -32.49% |
| 2014-12-31 | -32.01% |
| 2013-12-31 | -31.59% |
Related Metrics
About Teladoc Health, Inc.
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Charles Divita